Navigation Links
Avidity Biosciences Announces Publication on Targeting Therapeutic Oligonucleotides by Arthur A. Levin in the New England Journal of Medicine
Date:1/5/2017

LA JOLLA, Calif., Jan. 4, 2017 /PRNewswire/ -- Avidity Biosciences LLC, a biotechnology company advancing Antibody-siRNA Conjugates (ASCs) as a new class of precision medicines, today announced a publication entitled, "Targeting Therapeutic Oligonucleotides," in the January 5, 2017 issue of the New England Journal of Medicine.1 The publication, authored by Arthur A. Levin, Ph.D., executive vice president of research and development, appears in the Clinical Implications of Basic Research section.

In the publication, Dr. Levin summarizes the advantages of targeted strategies for the delivery of therapeutic oligonucleotides. 

"Recent work indicates that the usefulness of therapeutic oligonucleotides can be increased by conjugating oligonucleotides with targeting moieties so that they home to specific cell types," said Dr. Levin. "Targeted delivery was determined to result in a median effective dose that was one thirtieth of that associated with non-targeted delivery, which clearly underscored the potential advantage of the approach."

Levin continues, "There remains a need to target non-hepatic cells specifically and efficiently: a means to achieve this goal could lie in the exploitation of the natural heterogeneity of cell surface receptors."

Dr. Levin has an unparalleled track record and reputation in the field of nucleic acid-based therapeutics. Prior to his role at Avidity Biosciences, he held senior drug development roles at miRagen Therapeutics, Ionis Pharmaceuticals and Santaris Pharma. He has played key roles in the development of numerous oligonucleotides, including the first approved antisense NDAs and the first microRNA-targeted therapeutic in clinical trials. He has a combined three decades of experience in all aspects of drug development from discovery through drug registration, both in large pharma and biotech companies. Dr. Levin has published over 60 scientific articles and has several of the most cited reviews in the field. He serves as a director of the Oligonucleotide Therapeutics Society and holds several additional scientific organization affiliations and honors. He received a doctorate in toxicology from the University of Rochester and a bachelor's degree in biology from Muhlenberg College.

About Avidity Biosciences

Avidity Biosciences is a privately held biotech company pioneering a new class of precision medicines – Antibody-siRNA Conjugates (ASCs) – which combine the strengths of monoclonal antibodies and siRNA-based therapeutics. Avidity is collaborating with partners to discover and develop best-in-class drug candidates against important undrugged therapeutic targets. The company has entered research collaborations with leading biopharma companies and is actively seeking additional partnerships. Avidity has raised $25 million in venture financing from a top-tier group of sophisticated healthcare investors.  More information about Avidity Biosciences can be found on the company's website at www.aviditybiosciences.com.

1  Levin, A, Targeting therapeutic oligonucleotides. N Engl J Med 2016;376: 86-88.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/avidity-biosciences-announces-publication-on-targeting-therapeutic-oligonucleotides-by-arthur-a-levin-in-the-new-england-journal-of-medicine-300385825.html


'/>"/>
SOURCE Avidity Biosciences
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Biotech Stocks on Investors Radar -- Eleven Biotherapeutics, Illumina, Sangamo Biosciences, and CytRx
2. Neurocrine Biosciences Announces Chief Financial Officer Timothy P. Coughlin to Step Down
3. DuPont Industrial Biosciences to Begin New Research Aimed to Enable Global Access for Protein Medications
4. Roche announces termination of 2013 Development, Commercialization and License Agreement with Pacific Biosciences
5. ACEA Biosciences Presents Efficacy and Safety Data From AC0010 Phase I/II Clinical Trial for Treatment of Advanced Non-Small Cell Lung Cancer at the WCLC 2016 Conference
6. ACEA Biosciences Announces Data Presentation at WCLC 2016 Conference: New AC0010 Data to Be Presented
7. Vigene Biosciences Acquires the cGMP Manufacturing Facility and Assets of Omnia Biosciences
8. ACEA Biosciences Appoints Li Xu, M.D. as Chief Medical Officer
9. DuPont Industrial Biosciences and MIAVIT Announce Supply Agreement for Biogas Enzymes
10. Agro BioSciences Expands Probiotic Strain Portfolio
11. ARMO BioSciences Immunotherapy AM0010 Receives Orphan Drug and Fast Track Designations from the U.S. FDA for the Treatment of Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/13/2018)... ... November 12, 2018 , ... AseptiScope(TM), ... that two large U.S. studies, published last week, confirm pose a significant health ... Infection Control (AJIC) conclude that stethoscopes are often improperly or rarely disinfected. In ...
(Date:11/13/2018)... , ... November 13, 2018 , ... ... of the spine technology market last week that asserts it is still trending ... population. , Humad’s analysis describes market consolidation, pricing pressure and increased ...
(Date:11/13/2018)... Ore. (PRWEB) , ... November 13, 2018 , ... ... at Bio-Logic Aqua® Research Water Life Science® in Grants Pass, Oregon believes in ... Kleyne and Bio-Logic Aqua® Research Water Life Science® sponsors the Power of Water® ...
(Date:11/9/2018)... ... November 08, 2018 , ... uBiome, the leader ... Executive Officer and President of Andes Biotechnologies, to its Scientific Advisory Board. Joining ... brings to uBiome expertise on the genetic studies of hepatitis viruses. The appointment ...
Breaking Biology Technology:
(Date:12/5/2018)... ... December 04, 2018 , ... Slone Partners, North America’s leading ... Michael Mercer at Karius, Inc. as Chief Commercial Officer. Now responsible for developing, ... Karius' headquarters in Redwood City, California and report to CEO Mickey Kertesz Ph.D. ...
(Date:12/5/2018)... SAN DIEGO (PRWEB) , ... December 04, 2018 ... ... to leverage Fastec’s extensive expertise and existing IP in the development of innovative ... technology has been integrated into diverse systems from microfluidics to industrial machinery and ...
(Date:11/27/2018)... , ... November 26, 2018 , ... ... Brandon Wuerth, MD, Founder of the website IBDwatch and Gastroenterology Fellow at the ... scientists and doctors from around the world, Dr. Wuerth will bring to uBiome ...
Breaking Biology News(10 mins):